About InsightRx
InsightRx is a company based in San Francisco (United States) founded in 2015. InsightRx has raised $13.25 million across 3 funding rounds from investors including Canadian Imperial Bank of Commerce, Premier and OSF HealthCare. The company has 23 employees as of December 31, 2024. InsightRx offers products and services including InsightRX Nova, InsightRX Apollo, and Companion Applications. InsightRx operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter San Francisco, United States
- Employees 23 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13.25 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
Canadian Imperial Bank of Commerce
& 6 more
-
Employee Count
23
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InsightRx
InsightRx offers a comprehensive portfolio of products and services, including InsightRX Nova, InsightRX Apollo, and Companion Applications.
Platform for model-informed dosing to personalize patient treatments.
Tool for real-time analytics to enhance medication safety and efficacy.
Applications that integrate precision dosing in clinical trials.
People of InsightRx
Unlock access to complete
Unlock access to complete
Funding Insights of InsightRx
InsightRx has successfully raised a total of $13.25M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(22 May 2017)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Debt – Conventional - InsightRx | Valuation |
investors |
|
| Sep, 2019 | Amount | Series A - InsightRx | Valuation | HealthX Ventures | |
| May, 2017 | Amount | Series A - InsightRx | Valuation | GreatPoint Ventures , OSF HealthCare |
|
Investors in InsightRx
InsightRx has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Canadian Imperial Bank of Commerce, Premier and OSF HealthCare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed toward accessible digital healthcare solutions.
|
Founded Year | Domain | Location | |
|
Digital Health focused VC & Accelerator firm investing in the US
|
Founded Year | Domain | Location | |
|
Early & Expansion stage tech-focused VC firm investing in geographies such as the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by InsightRx
Financial Statements - InsightRx
Insightrx Comparisons
Competitors of InsightRx
InsightRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
Diagnostic services are provided through laboratories and radiology units.
|
Latest news on Insightrx
Frequently Asked Questions about InsightRx
InsightRx was founded in 2015 and raised its 1st funding round 2 years after it was founded.
InsightRx is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
InsightRx is a funded company, having raised a total of $13.25M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.25M, raised on May 22, 2017.
As of Dec 31, 2024, the latest employee count at InsightRx is 23.
InsightRx was founded in 2015 in San Francisco, United States, as a precision medicine company. A software platform is provided to determine patient-specific drug dosages, utilizing machine learning, mathematical models, demographics, physiological traits, pharmacogenomic data, drug concentrations, and biomarkers. Services are targeted at clinical pharmacists and physicians in the healthcare sector to minimize adverse events, enhance patient outcomes, and lower hospital expenses.
InsightRx's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
InsightRx offers InsightRX Nova, InsightRX Apollo, and Companion Applications.
InsightRx has 7 investors. Key investors include Canadian Imperial Bank of Commerce, Premier, OSF HealthCare, HealthX Ventures, and Rock Health.